Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 15;8(2):51-58.
doi: 10.4291/wjgp.v8.i2.51.

Non-alcoholic fatty liver disease and cardiovascular risk

Rashmee Patil  1 , Gagan K Sood  1
Affiliations
Review

Non-alcoholic fatty liver disease and cardiovascular risk

Rashmee Patil et al. World J Gastrointest Pathophysiol. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with insulin resistance and metabolic syndrome. The spectrum of disease ranges from simple steatosis to steatohepatitis and progression to cirrhosis. Compelling evidence over the past several years has substantiated a significant link between NAFLD and cardiovascular disease ranging from coronary artery disease to subclinical carotid atherosclerosis. Close follow up, treatment of risk factors for NAFLD, and cardiovascular risk stratification are necessary to predict morbidity and mortality in this subset of patients.

Keywords: Cardiovascular risk; Coronary artery disease; Non-alcoholic fatty liver disease; Outcomes; Steatosis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Patil R and Sood GK have no conflicts of interest to report.

References

    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231. - PubMed
    1. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27–38. - PubMed
    1. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263–2271. - PMC - PubMed
    1. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005;112:2130–2137. - PubMed
    1. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995;142:699–708. - PubMed